Back to results
US 2024/0182572 A1Published application
Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
AssigneeOse Immunotherapeutics
InventorsNICOLAS POIRIER, AURORE MORELLO, CAROLINE MARY, JUSTINE DURAND
Life of this patent
Estimating the term…
Abstract
The present invention relates to bifunctional molecules having a particular scaffold and their uses.
Claims17
1-16. (canceled).
A bifunctional molecule comprising a single antigen binding domain that binds to a target specifically expressed on immune cells surface and a single immune-stimulating moiety,
- wherein the molecule comprises a first monomer comprising an antigen-binding domain covalently linked via C-terminal end to N-terminal end of a first Fc chain, optionally via a peptide linker, and a second monomer comprising a complementary second Fc chain devoid of antigen-binding domain and of the immune-stimulating moiety;
- wherein either i) the immune-stimulating moiety is covalently linked to the C-terminal end of said first Fc chain, optionally via a peptide linker;
- or ii) the single antigen binding domain comprises a heavy variable chain and a light variable chain and the immune-stimulating moiety is covalently linked to the C-terminal end of the light chain;
- wherein the target specifically expressed on immune cells surface is selected from the group consisting of PD-1, CD28, CTLA-4, BTLA, TIGIT, CD160, CD40L, ICOS, CD27, OX40, 4-1BB, GITR, HVEM, Tim-1, LFA-1, TIM3, CD39, CD30, NKG2D, LAG3, B7-1, 2B4, DR3, CD101, CD44, SIRPG, CD28H, CD38, CD3, PDL2, and PDL1;
- and
- wherein the immune-stimulating moiety is selected from the group consisting of SIRPγ, SIRPα, SIRPβ, CD80, CD86, LIGHT, CTLA-4, TIGIT, CD40L, OX40L, APRIL and GITRL or a fragment thereof comprising the extracellular part thereof or a variant thereof having at least 80% of identity with the wildtype protein or the extracellular part thereof.
3 more elements
Dependencies are inferred from the claim text.